Mark Alan Goldberg

Filings by Mark Alan Goldberg span 3 companies, the busiest being Blueprint Medicines Corp, ImmunoGen, Inc. and Crescent Biopharma, Inc. Over a trading history stretching from 18 May 2021 to 17 July 2025, the count stands at 17 filings.

Every open-market trade on record is a purchase: 1 purchase worth €270k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 13 share grants and 1 option exercise.

Most recently, on 21 July 2025, the filings show a transaction in Blueprint Medicines Corp. The most recent open-market purchase was published on 7 March 2022, 1,686 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.